Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: Coronary artery disease regression single photon emission computed tomography monitoring trial

Journal of the American College of Cardiology

Volumn 42, Issue 4, 2003, Pages 600-610

  Schwartz, Ronald G ^a,c   Pearson, Thomas A ^a   Kalaria, Vijay G ^b   Mackin, Maria L ^a   Williford, Daniel J ^a   Awasthi, Ashish ^a   Shah, Abrar ^a   Rains, Adam ^a   Guido, Joseph J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NICOTINIC ACID; NITRATE; PRAVASTATIN; THALLIUM 201; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DYSLIPIDEMIA; EXERCISE TEST; FATIGUE; FEMALE; HEART MUSCLE PERFUSION; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MALE; MYALGIA; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; REST; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0042354586     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00767-8     Document Type: Article

References (36)

1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
2. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary, events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events (CARE) trial investigators. N Engl J Med 1996;335:1001-9.
4. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
5. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1353-9.
6. Tonkin A, Colquhoun M, Emberson D, et al., for the LIPID Study Group. Effects of pravastatin in 3,260 patients with unstable angina: results from the LIPID study. Lancet 2000;356:1871-5.
7. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
8. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging: a diagnostic tool comes of age. Circulation 1991;83:363-812.
9. Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease. Incremental prognostic value and use in risk stratification. Circulation 1996;93:905-14.
10. Sharir T, Germano G, Kavanagh PB, et al. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. Circulation 1999;100:1035-42.
11. Shaw LJ, Hachamovitch R, Berman DS, et al., for the Economics of Noninvasive Diagnosis (END) Multicenter Study Group. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. J Am Coll Cardiol 1999;33:661-9.
12. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for prediction of cardiac death. Circulation 1998;97:535-43.
13. Gould KL, Ornish D, Scherwitz L, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 1995;274:894-901.
14. Pancholy SB, Fattah AA, Kamal AM, et al. Independent and incremental prognostic value of exercise thallium single-photon emission computed tomographic imaging in women. J Nucl Cardiol 1995;2:110-6.
15. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
16. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
17. Schwartz RG, Pearson TA. Can single photon emission computed tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia? J Nucl Cardiol 1997;4:555-68.
18. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
19. Czernin J, Barnard RJ, Sun KT, et al. Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation 1995;92:197-204.
20. Huggins GS, Pasternak RC, Alpert NM, et al. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 1998;98:1291-6.
21. Mostaza JM, Gomez MV, Gallardo F, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000;35:76-82.
22. Schwartz RG. Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy (editorial). J Nucl Cardiol 2001;8:528-32.
23. O'Rourke RA, Chaudhuri T, Shaw L, et al. Resolution of stress-induced myocardial ischemia during aggressive medical therapy as demonstrated by single photon emission computed tomography imaging. Circulation 2001;103:2315.
24. Yokoyama I, Yonekura K, Inoue Y, et al. Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J Nucl Cardiol 2001;8:445-51.
25. Guethlin M, Kasel AM, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999;99:475-81.
26. Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usualcare cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol 2003;41:263-72.
27. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
28. Liu YH, Sinusas AJ, Deman P, Zaret BL, Wackers FJT. Quantification of SPECT myocardial perfusion images: methodology and validation of the Yale-CQ method. J Nucl Cardiol 1999;6:190-203.
29. Zar JH. Biostatistical Analysis. 4th edition. Saddle River, NJ: Prentice Hall, 1999.
30. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for cad with angiographically smooth coronary vessels. Circulation 1990;81:491-7.
31. Zeiher AM, Drexler H, Wollsclaeger H, et al. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1954-92.
32. Dakik HA, Kleiman NS, Farmer JA, et al. Intensive medical therapy versus coronary angioplasty for suppressing myocardial ischemia in survivors of acute myocardial infarction: a prospective randomized pilot study. Circulation 1998;98:2017-23.
33. Berman DS, Kang X, Schisterman EF, et al. Serial changes on quantitative myocardial perfusion SPECT in patients undergoing revascularization or conservative therapy. J Nucl Cardiol 2001;8:428-37.
34. Brown KA. Do stress echocardiography and myocardial perfusion imaging have the same ability to identify the low-risk patient with known or suspected CAD? Am J Cardiol 1998;81:1050-3.
35. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97:1129-35.
36. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5.